CHROMADEX CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt SecuritiesIndenture • June 12th, 2020 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
Indenture, dated as of [●], 20__, among ChromaDex Corporation, a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):
ChromaDex Corporation and _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ ChromaDex Corporation Form of Debt Securities Warrant AgreementWarrant Agreement • June 22nd, 2023 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between ChromaDex Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
CHROMADEX CORPORATION Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • June 12th, 2020 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
ChromaDex Corporation and _____________, As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of __________ ChromaDex Corporation Form of Common Stock Warrant AgreementWarrant Agreement • June 22nd, 2023 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between ChromaDex Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
INDEMNITY AGREEMENTIndemnification Agreement • December 16th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
This Indemnity Agreement (this “Agreement”) dated as of ___________ _____, 20__, is made by and between ChromaDex Corporation, a Delaware corporation (the “Company”), and _________________ (“Indemnitee”).
PLACEMENT AGENCY AGREEMENT January 31, 2012Placement Agency Agreement • February 1st, 2012 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 24th, 2012 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 21st day of February, 2012, by and between ChromaDex Corporation, a Delaware corporation (the “Company”) with an address of 4400 Biscayne Boulevard, Miami, Florida 33137 and Debra Heim, an individual residing at 4265 Hyacinth Circle North, Palm Beach Gardens, Florida 33410 (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean January 22, 2012.
SUBSCRIPTION AGREEMENTSubscription Agreement • October 18th, 2013 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the last date set forth on the signature page hereof between ChromaDex Corporation, a Delaware corporation (the “Company”), and the undersigned (the “Subscriber”). The Company is conducting a private placement of up to $3,500,000 (the “Offering”) of shares (the “Shares” or the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $0.85 per Share.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 11th, 2022 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 10, 2022, between ChromaDex Corporation, a Delaware corporation (the “Company”), and Société des Produits Nestlé SA, a société anonyme organized under the laws of Switzerland (the “Purchaser”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 3rd, 2022 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of September 30, 2022, by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), and each purchaser signatory hereto (each, a “Purchaser” and collectively to the extent there is more than one Purchaser, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 6th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
LEASE 10900 WILSHIRE, L.L.C., a Delaware limited liability company, Landlord and CHROMADEX, INC., a California corporation, Tenant for 10900 Wilshire Boulevard Los Angeles, California July 6, 2017Lease Agreement • March 7th, 2019 • ChromaDex Corp. • Medicinal chemicals & botanical products • California
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 3rd, 2022 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 30, 2022, by and among ChromaDex Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively to the extent there is more than one Purchaser, the “Purchasers”).
CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for MEGAN JORDANExecutive Employment Agreement • March 12th, 2021 • ChromaDex Corp. • Medicinal chemicals & botanical products • California
This Executive Employment Agreement (this “Agreement”) is entered into as of July 23, 2019 (the “Effective Date”), by and between Megan Jordan (“Executive”) and ChromaDex Corporation, a Delaware corporation (the “Company”).
SECURITY AGREEMENTSecurity Agreement • March 29th, 2013 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This SECURITY AGREEMENT, dated as of March 28, 2013 (this “Agreement”), is by and between NEUTRISCI INTERNATIONAL INC., a corporation incorporated pursuant to the laws of the Province of Alberta (the “Company”), and CHROMADEX CORPORATION, a corporation incorporated pursuant to the laws of the state of Delaware (together with its successors and assigns, the “Secured Party”).
LEASE FOR PREMISES LOCATED AT 1751 SOUTH FORDHAM STREET, SUITE F, LONGMONT, COLORADO BETWEEN CHROMADEX ANALYTICS, INC. AS TENANT AND LONGMONT DIAGONAL INVESTMENTS LLC AS LANDLORDLease Agreement • April 20th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • Colorado
PROJECT: 1751 South Fordham Street, Longmont, CO 80503 ("Project") PREMISES: Suite F (totaling 10,052 net rentable square feet) ("Premises") LANDLORD: LONGMONT DIAGONAL INVESTMENTS LLC, a Delaware limited liability company ("Landlord") LEASE DATED: _________________, 2016 ("Lease")
MINING OPTION AGREEMENTMining Option Agreement • January 18th, 2007 • Cody Resources, Inc. • British Columbia
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 6th, 2017 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 3, 2017, between ChromaDex Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 24th, 2008 • Cody Resources, Inc. • Mining & quarrying of nonmetallic minerals (no fuels) • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of this 14th day of April 2008, by and between CHROMADEX, INC., a California corporation (“Employer”), and FRANK L JAKSCH, JR. (“Employee”).
SEVENTH AMENDMENTManufacturing and Supply Agreement • November 3rd, 2021 • ChromaDex Corp. • Medicinal chemicals & botanical products
This Seventh Amendment to the Manufacturing and Supply Agreement (the "Seventh Amendment") is made and effective as of August 2, 2021 (the "Seventh Amendment Effective Date") by and between W. R. Grace & Co. ("GRACE") and ChromaDex, Inc. ("ChromaDex").
FIRST AMENDMENT TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE — NETStandard Industrial/Commercial Multi-Tenant Lease • November 12th, 2008 • ChromaDex Corp. • Medicinal chemicals & botanical products
FIRST AMENDMENT (“First Amendment”) made as of June 26, 2008, to that certain Standard Industrial/Commercial Multi-Tenant Lease — Net (“Lease”) dated for reference purposes only December 19, 2006, by and between SCIF Portfolio II, LLC, a California limited liability company (the “Lessor”) and Chromadex, Inc., a California corporation (the “Lessee”), for that certain approximate 7,536 square foot space (hereinafter the “Original Premises”) commonly known by the address 10005 Muirlands Blvd., Suite G, 1st Floor, and Suite K, 92618.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 22nd, 2010 • ChromaDex Corp. • Medicinal chemicals & botanical products • California
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of this 19th day of April 2010, by and between CHROMADEX, INC., a California corporation ("Employer"), and FRANK L JAKSCH, JR. ("Employee").
FIRST AMENDMENT TO THE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND CHROMADEX INC.License Agreement • November 6th, 2014 • ChromaDex Corp. • Medicinal chemicals & botanical products
This first amendment (the “First Amendment”), dated Sept 5th, 2014 (the “Effective Date”), is made by and between The Regents of the University of California (“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Irvine located at 5171 California Ave, Suite 150 CA 92697-7700 and ChromaDex Inc. (“Licensee”) having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 and amends the license agreement with Licensee, dated September 8, 2011 with UC Agreement Control Number 2012-04-0120 (the “License Agreement”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • February 13th, 2012 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
This Indemnification Agreement (the "Agreement") is made as of the date indicated below between ChromaDex Corporation, a Delaware corporation (the "Company"), and the undersigned individual ("you"). In consideration of your continued service to the Company or one of its subsidiaries, the Company hereby binds itself as follows (capitalized terms are generally defined in Exhibit A):
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 11th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March , 2016, between ChromaDex Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
FIRST AMENDMENT TOExclusive License Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products
THIS FIRSTAMENDMENT (“Amendment”) is effective as of June 13, 2016, by and between the TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and CHROMADEX INC. having its principal place of business at 10005 Muirlands Blvd., Suite G, Irvine, California 92618; hereinafter called Company. (hereinafter “Company”).
INTEREST PURCHASE AGREEMENTInterest Purchase Agreement • November 12th, 2015 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
This Interest Purchase Agreement (this “Agreement”) is entered into as of the 28th day of August, 2015 by and between Healthspan Research LLC, a Delaware limited liability company (the “Company”), and the undersigned investor (the “Investor”).
TAG-ALONG AGREEMENTTag-Along Agreement • June 24th, 2008 • Cody Resources, Inc. • Mining & quarrying of nonmetallic minerals (no fuels) • Mississippi
THIS TAG-ALONG AGREEMENT, dated effective as of December 31, 2005 is made and entered into by and among FRANK LOUIS JAKSCH, SNR. & MARIA JAKSCH, Trustees of the Jaksch Family Trust, MARGERY GERMAIN, LAUREN GERMAIN, EMILY GERMAIN, LUCIE GERMAIN, FRANK LOUIS JAKSCH JR. (each, individually, a “Founder” and collectively, the “Founders”), CHROMADEX, INC., a California corporation (the “Company”) and THE UNIVERSITY OF MISSISSIPPI RESEARCH FOUNDATION, a Mississippi nonprofit corporation (the “Shareholder”).
T +1 410.531.4000 W. R. Grace & Co.-Conn. 7500 Grace Drive Columbia, MD 21044Take or Pay Purchase Agreement • November 12th, 2015 • ChromaDex Corp. • Medicinal chemicals & botanical products
ChromaDex, Inc. (“ChromaDex”) currently purchases nicotinamide riboside chloride (the “Product”) from W. R. Grace & Co.-Conn. (“Grace”) under terms agreed to by both ChromaDex and Grace. Notwithstanding any such terms, ChromaDex and Grace agree that the following purchase obligation and related terms shall apply, effective as of the date of this letter agreement:
CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 12th, 2022 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth,
MEMBERSHIP INTEREST PURCHASE AGREEMENTMembership Interest Purchase Agreement • May 11th, 2017 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”) is made as of March 12, 2017, by and among (i) Robert N. Fried, an individual (“R. Fried”), (ii) Dr. Charles Brenner, an individual (“Dr. Brenner”), (iii) Jeffrey Allen, an individual (“J. Allen”; each of R. Fried, Dr. Brenner, and J. Allen, a “Seller”, and collectively the “Sellers”), and ChromaDex Corporation, a Delaware corporation (“Buyer”). Sellers and Buyer are collectively referred to herein as the “Parties” and each individually as a “Party.”
TECHNOLOGY LICENSE AGREEMENT between THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK and ChromaDex, Inc.Technology License Agreement • August 12th, 2008 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Technology License Agreement (“Agreement”) is effective as of June 30, 2008 (“Effective Date”) by and between The Research Foundation of State University of New York, on behalf of University at Buffalo, a non-profit corporation organized and existing under the laws of the State of New York (“Foundation”) and ChromaDex Inc., a California corporation, with an address at 10005 Muirlands Boulevard, Suite G, Irvine, California 92618 (“Licensee”).
LIMITED LIABILITY COMPANY AGREEMENT OF HEALTHSPAN RESEARCH, LLC Dated as of August 28, 2015Limited Liability Company Agreement • November 12th, 2015 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
THIS LIMITED LIABILITY COMPANY AGREEMENT, is entered into as of August 28, 2015, by and among the Members (as defined below) and the Company (as defined below).
SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • February 17th, 2012 • ChromaDex Corp. • Medicinal chemicals & botanical products • California
THIS SEPARATION AND RELEASE AGREEMENT (the “Agreement”) is entered into as of the 13th day of February, 2012, by and between William Spengler (the “Employee”) and Chromadex, Inc. and any parents, subsidiaries, or affiliates of the Company, including, without limitation, Chromadex, Corp. and ChromaDex Analytics, Inc. (collectively referred to herein as the “Company”).
ContractConvertible Note • March 29th, 2013 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
THIS NOTE AND THE SHARES OF SERIES I PREFERRED SHARES ISSUABLE UPON CONVERSION HEREOF AND THE CLASS A COMMON SHARES ISSUABLE UPON THE CONVERSION OF THE SERIES I PREFERRED SHARES (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR RECEIPT BY THE MAKER OF AN OPINION OF COUNSEL IN FORM, SUBSTANCE AND SCOPE REASONABLY SATISFACTORY TO THE MAKER THAT THE SECURITIES MAY BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF, UNDER AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND SUCH STATE SECURITIES LAWS. DELIVERY OF THE SECURITIES MAY NOT CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. IF THESE SECURITIES ARE BEING SOLD AT ANY TIME THE COMPANY IS A “FOREIGN ISSUER” AS DEFINED IN RULE 902 UNDER THE 1933 ACT, A NEW NOTE CERTIFICATE REPRESENTING THE SECURITIES, BEARING NO LEGEND, T
